InVet 2020, 22 (1): 1-10 ISSN 1514-6634 (impreso) ISSN 1668-3498 (en...
Acquired myasthenia gravis (MGA) is an immnunomediated disease that affects the canine species, caused by the presence of antibodies against postsynaptic nicotinic choloreceptors and the consequent interference in the neuromuscular transmission of voluntary muscles. Six canines with ocular alteratio...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo publishedVersion |
| Lenguaje: | Español |
| Publicado: |
Universidad de Buenos Aires. Facultad de Ciencias Veterinarias.
2020
|
| Materias: | |
| Acceso en línea: | http://repositoriouba.sisbi.uba.ar/gsdl/cgi-bin/library.cgi?a=d&c=pveterinaria/invet&cl=CL1&d=HWA_3710 https://repositoriouba.sisbi.uba.ar/gsdl/collect/pveterinaria/invet/index/assoc/HWA_3710.dir/3710.PDF |
| Aporte de: |
| Sumario: | Acquired myasthenia gravis (MGA) is an immnunomediated disease that affects the canine species, caused by the presence of antibodies against postsynaptic nicotinic choloreceptors and the consequent interference in the neuromuscular transmission of voluntary muscles. Six canines with ocular alterations and clinical signology compatible with MGA from the Hospital School of the Faculty of Veterinary Sciences of the University of Buenos Aires were diagnosed by the presence of antibodies against serum acetylcholine receptor (ACRA). These animals showed visual deficits, with P100 waves of diminished amplitude values in evoked potentials (VEP). They were treated with 0.5 mg / kg pyridostigmine bromide orally every 12 h, for 30 days and after this period, they were re-evaluated. The VEP obtained after treatment showed that 80% (5/6) of the animals increased the amplitude of the P100 wave. Visual evoked potentials offer a non-invasive method that identifies the central effects of AMS and its therapeutic evolution. |
|---|